Sunkersett, Gauri
AbbVie (United States)
2 papers on CoChat
Most cited papers
- Verified
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 41
- Verified
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Falchi, L., Sureda, A., Leppä, S., Vermaat, J. S. P., Nijland, M., Christensen, J. H., de Vos, S., Holte, H., Merryman, R. W., Lugtenburg, P. J., et al. (2025) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 15
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free